Clinical Trial Update: Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults [Phase 4]

View source ↗

Summary

Phase 4 pilot trial evaluating two schedules of the 4CMenB meningococcal vaccine in adolescents and young adults has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• 4CMenB vaccine (Bexsero) (4CMenB vaccine)

Snippet

Sponsor: Canadian Immunization Research Network | Conditions: Meningococcal Serogroup B | Phase 4 | Status: COMPLETED